Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, you are correct, tough as it is for some to admit. Also zero institutional investment at these sub dollar prices.
My gawd, if you look at his LinkedIn photo, he is sitting down to a plate of tacos!
Check it out!
Valuation of the RGBP patents is not 150 billion as some claim..
It's worth 150 trillion!
Ah can't do the math right now but that equals a gazillion dollars per share!
That's enough to pay off the national debt and give everyone in the world free admission to Dollyland!
Do us up real proud this week Koots!
Or unless you're glued to your PC or android device. I've seen OTC pink stocks evaporate in minutes.
OTC gamblers were warned. The new bagholders will soon be as testy as this one.
Always set stop losses when gambling on the OTC! A cardinal rule.
Big pharma is going to need much more than just a patent. Doesn't work that way.
But you're right, Koots doesn't have the ammo to get anything off the ground. Witness dCellVax, HemaXellerate, Zanders gastro treatment for dogs, etc.
I'll add to that. The reason Koots is scrambling is that he needs money. Badly. He owes too much to former employees and to ChemDiv. Over two million dollars.
When things came to a head he scrambled at the last minute. Any deals he strikes with his patents in the future will be centered around his personal needs, not the best interests of his fans. IMHO.
Yeh, I'll explain it real good for ya...
Despite the promise of these therapies, none has amounted to a hill of beans under the stewardship of Koots.
Remember, I've been with Koots for ten years and know him better than anyone on this board. He's more concerned with feeding his fat gut and sailing on his six days off per week than bringing any of these patents to life.
A company is only as good as its management. A cardinal rule.
I was interested in the NR2F6 agonist/antagonist many years ago and thought Koots had something.
He has since given me the impression that he is simply playing a shell game with his spin-offs and dilution.
Yep, shocking news. You heard it here first.
That's it in a nutshell.
Wake up peoples!
150 billion in patents means $40 per share! It's math! This will go to $50 per share just because it's SUPER MEGA SCIENCE!!
Someone said it, I believe it and that settles it..Thets logic right there!
This will fly past the moon and probably never return!!
Whew..I'm glad I got that off my chest!
Koots needs to get to work..
First, wipe the the taco grease from the chins and then get busy Koots!
Taking off..
I think I heard this about 1000 times...
Any biotech experts on the forum here that can give us a real idea of the importance of NR2F6?
I'd like to be a believer but when Koots cooks up NR2F6 spinoffs with CBD, I just roll my eyes. Why not a cannabinoid with some real value as an anti-tremor medicine like CBG?
As usual, Koots is late to the party on this one.
CBD? Pure quackery. This is the kind of BS that finally pissed me off.
But there is no reference in the physicians quote specifically about RGBP.